Table 1 Demographic and clinical characteristics of patients with and without DILI

Age at TB diagnosis, years

 Mean (SD)

47

(19)

48

(18)

0.695

0.013

  < 30

1407

(23.8)

243

(21.1)

0.001

0.167

 30–49

1843

(31.1)

359

(31.2)

 50–69

1773

(29.9)

414

(35.9)

 70 + 

897

(15.1)

135

(11.8)

Gender

0.105

0.053

 Male

4051

(68.4)

759

(65.9)

 Female

1869

(31.6)

392

(34.1)

Race

0.668

0.018

 Han

5792

(97.8)

1129

(98.1)

 Others

128

(2.2)

22

(1.9)

Treatment status

0.472

0.025

 Initial

5464

(92.3)

1070

(93.0)

 Retreatment

456

(7.7)

81

(7.0)

Diagnosis site

0.042

 Lung

5509

(93.1)

1083

(94.1)

 Other sites

411

(6.9)

68

(5.9)

Education

0.006

0.112

 Illiteracy

2248

(38.0)

488

(42.4)

 Semi-literate

212

(3.6)

37

(3.2)

 Undergraduate

3289

(55.6)

582

(50.6)

 Bachelor

171

(2.9)

44

(3.8)

Profession

0.381

0.072

 Industry

3281

(55.4)

625

(54.3)

 Clothing

1718

(29.0)

329

(28.6)

 Retirees

416

(7.0)

85

(7.4)

 Government

235

(4.0)

57

(5.0)

 Others

139

(2.3)

22

(1.9)

 Student

131

(2.2)

33

(2.9)

Ratio of ULN of serological markers^a Median (IQR)

 ALT

0.44

(0.27,0.66)

0.52

(0.30,0.66)

 < 0.001

0.104

 ALP

0.68

(0.56,0.82)

0.68

(0.55,0.82)

0.871

0.047

 Tbil

0.52

(0.38,0.71)

0.54

(0.40,0.74)

0.005

0.072

Serological markers status

 Abnormal ALT

273

(4.6)

91

(7.9)

 < 0.001

0.136

 Abnormal ALP

400

(6.8)

100

(8.7)

0.023

0.072

 Abnormal Tbil

366

(6.2)

87

(7.6)

0.093

0.054

Comorbidities

 Diabetes

599

(10.1)

102

(8.9)

0.211

0.043

 Hypertension

1108

18.7

216

18.8

1.000

0.001

 Liver-related diseases^b

624

10.5

224

19.5

 < 0.001

0.252

 HBV

105

1.8

17

1.5

0.560

0.023

Medication

 TCM

1250

(21.1)

323

(28.1)

 < 0.001

0.162

 Hepatoprotective agents^c

1971

(33.3)

486

(42.2)

 < 0.001

0.192

 PZA

1105

(18.7)

304

(26.4)

 < 0.001

0.186

 RIF

590

(10.0)

121

(10.5)

0.610

0.018

 INH

1000

(16.9)

267

(23.2)

 < 0.001

0.158